search
Back to results

AI Augmented Training for Skin Specialists (AISC-SS)

Primary Purpose

Melanoma, Skin Cancer

Status
Enrolling by invitation
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
DermLoop Learn
Sponsored by
Herlev Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Melanoma focused on measuring Artificial Intelligence, Education, Diagnostic Accuracy, Skin Cancer, Melanoma, Feedback loop

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Doctors are required to work at a specialized skin department (dermatology or plastic surgery or the like).
  • Doctors must be registered authorized health personnel

Exclusion Criteria:

  • Doctors that have previously received access to the DermLoop Learn educational intervention
  • Doctors with less than 2 months left of their affiliation with their current department of employment

Sites / Locations

  • Herlev Hospital
  • Gentofte Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

No Intervention

Arm Label

Group A

Group B

Arm Description

This group will receive access to the AI augmented digital online educational system and its two modules (Training Module and Clinical Feedback Module). They will receive continuous clinical feedback on their registered lesions.

This group is withheld their access to the AI augmented digital online educational system for 2 months. After the 2 months delay, the subjects in the group are given the same access as the participants in Group A.

Outcomes

Primary Outcome Measures

Dose/Response
Dose/response between hours spent with the education system and change in diagnostic accuracy for the participating doctors

Secondary Outcome Measures

BMR
Difference in Benign to Malignant ratio (BMR) in treated/referred/sent home lesions suspected of skin cancer.
Multiple-Choice-Questionnaire predictability of diagnostic accuracy
Correlation between diagnostic accuracy and score measured on the MCQ at baseline and at 0 and 2 months.
Referrals
Change in the amount of referrals between the control and intervention group of the departments of dermatology to the departments of plastic surgery in the time before and after the intervention.

Full Information

First Posted
February 12, 2021
Last Updated
December 5, 2022
Sponsor
Herlev Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04758988
Brief Title
AI Augmented Training for Skin Specialists
Acronym
AISC-SS
Official Title
Artificial Intelligence Augmented Training in Skin Cancer Diagnostics for Skin Cancer Specialists
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Enrolling by invitation
Study Start Date
September 15, 2021 (Actual)
Primary Completion Date
March 28, 2024 (Anticipated)
Study Completion Date
September 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Herlev Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Background: The worldwide incidence of skin cancer has been rising for 50 years, in particular the incidence of malignant melanoma has increased approx. 2-7% annually and is the most common cancer amongst Danes aged 15-34. Currently there is a significant amount of misdiagnosis of skin cancer and mole cancer, and most excised skin lesions are benign. Previous studies have shown that there is no significant increase in doctors diagnostic accuracy during the first 6 years of clinical work. The resources spend on healthy people could be put to better use, if the Benign-Malignant Ratio could be lowered. This could potentially be done by better educating the doctors during their everyday clinical practice. Aim: The aim of this study is to investigate the dose/response effect of an AI augmented training and clinical feedback on the diagnostic accuracy of skin cancer and clinical decisions among doctors from specialized skin cancer centers. Research question: How much specialized doctors need to train before their diagnostic accuracy and clinical decisions change?
Detailed Description
Design: This study is a superiority trial designed as an international multicenter randomized controlled trial of doctors in highly specialized centers that diagnose and/or treat skin- and mole cancer. Randomization Eligible participants will be randomized into either the intervention or control group, ratio 1:1. Intervention: The participants of group A are given access to a digital educational online system developed by the research group, are asked to register all skin lesions seen with a registration app (clinical and dermoscopic photos and clinical data), also developed by the research group, and will be given clinical feedback on every registered skin lesion. Participants in group B are also asked from day one to register all skin lesions and will receive feedback on these as the participants of group A, but are withheld their access to the digital educational online system for 2 months. Feedback on removed/biopsied skin lesions is given directly from the pathologist, who in turn are given easy access to photographs and clinical data of the patient and skin lesion in question. Statistics: The average increase in diagnostic accuracy for the population of participating doctors as an effect of the hours spent with the digital educational online system is calculated using Generalized Estimating Equations (GEE). As benign lesions can be excised/treated for other reasons than suspicion of malignancy we will analyze correctly diagnosed benign lesions treated for different reasons (cosmetic or functional complaints etc.) separately. We expect a majority of registered lesions to be benign, despite most of the patients already having been seen by GPs before referral. Ethical considerations: Patient participation contains no immediate strain or discomfort for the patient, and no change to current clinical practice, as dermoscopic evaluation is part of the clinical examination of skin lesions. The images captured are stored safely and anonymously with no risk for the patient. With the current low diagnostic accuracy of young doctors the educational nature of the intervention justifies the study for the sake of all future patients with skin lesions that are less likely to be misdiagnosed. Educational interventions on doctors do not require approval by The National Committee on Health Research Ethics in Denmark. However ethical considerations have been made and the project is in concordance with the Helsinki Declaration II.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Melanoma, Skin Cancer
Keywords
Artificial Intelligence, Education, Diagnostic Accuracy, Skin Cancer, Melanoma, Feedback loop

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A randomized superiority clinical trial. Participating doctors are randomized to either group A or B in a 1:1 ratio.
Masking
Outcomes Assessor
Masking Description
Participating doctors are either given access to an AI augmented digital educational online system or not. During the study period, doctors of both groups are registering skin lesions they encounter in their daily practice using the same hardware and software. The expert dermatologists that evaluate the registered skin lesions are unaware of the registering doctors allocation.
Allocation
Randomized
Enrollment
70 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group A
Arm Type
Other
Arm Description
This group will receive access to the AI augmented digital online educational system and its two modules (Training Module and Clinical Feedback Module). They will receive continuous clinical feedback on their registered lesions.
Arm Title
Group B
Arm Type
No Intervention
Arm Description
This group is withheld their access to the AI augmented digital online educational system for 2 months. After the 2 months delay, the subjects in the group are given the same access as the participants in Group A.
Intervention Type
Other
Intervention Name(s)
DermLoop Learn
Intervention Description
DermLoop Learn is our AI augmented digital online educational system with case training on a library of 10,000+ benign and malignant skin lesion as well as written learning modules for the most common skin lesion diagnosis.
Primary Outcome Measure Information:
Title
Dose/Response
Description
Dose/response between hours spent with the education system and change in diagnostic accuracy for the participating doctors
Time Frame
2 years
Secondary Outcome Measure Information:
Title
BMR
Description
Difference in Benign to Malignant ratio (BMR) in treated/referred/sent home lesions suspected of skin cancer.
Time Frame
2 years
Title
Multiple-Choice-Questionnaire predictability of diagnostic accuracy
Description
Correlation between diagnostic accuracy and score measured on the MCQ at baseline and at 0 and 2 months.
Time Frame
2 months
Title
Referrals
Description
Change in the amount of referrals between the control and intervention group of the departments of dermatology to the departments of plastic surgery in the time before and after the intervention.
Time Frame
2 years

10. Eligibility

Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Doctors are required to work at a specialized skin department (dermatology or plastic surgery or the like). Doctors must be registered authorized health personnel Exclusion Criteria: Doctors that have previously received access to the DermLoop Learn educational intervention Doctors with less than 2 months left of their affiliation with their current department of employment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gustav G Nervil, MD
Organizational Affiliation
Herlev Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Herlev Hospital
City
Copenhagen
ZIP/Postal Code
2730
Country
Denmark
Facility Name
Gentofte Hospital
City
Copenhagen
ZIP/Postal Code
2900
Country
Denmark

12. IPD Sharing Statement

Learn more about this trial

AI Augmented Training for Skin Specialists

We'll reach out to this number within 24 hrs